MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Changes in botulinum toxin dosing in cervical dystonia over 7 years

S. Rafee, M. Hutchinson (Dublin, Ireland)

Meeting: 2022 International Congress

Abstract Number: 533

Keywords: Botulinum toxin: Clinical applications: dystonia, Dystonia: Etiology and Pathogenesis, Dystonia: Treatment

Category: Dystonia: Clinical Trials and Therapy

Objective: To assess changes in botulinum toxin dosing over the course of illness of cervical dystonia.

Background: Muscle specific botulinum toxin injections remains the main and only effective therapy available for the focal dystonias. Over the short term the injections are safe and well tolerated. Typical duration of action is approximately 10 weeks. Botulinum toxin is also required for the duration of the disease which is lifelong. Due to the rarity of this disorder, changes in dosing over the long term use of botulinum toxin remains under studied.

Method: We conducted a retrospective review of patients with cervical dystonia who received botulinum toxin for 7 years. Patients were included if they were diagnosed in our movement disorders clinic, received all their treatment at our centre and were treated with botulinum toxin from diagnosis. Patients were excluded if they had a diagnosis of any other neurological disorders or if they were receiving botulinum toxin treatment for any other condition. Generally, patients have more than one muscle injected so total dose at each therapy session was calculated and tracked over the course of the disease.

Results: 19 patients met our criteria for inclusion within this time period. All patients received 3 monthly botulinum toxin injections. Patients had torticollis or both torticollis and laterocollis. Only 3 patients had associated tremor. Mean toxin dosing at presentation was 123u (range 75u to 250u). Two patients had a decrease in toxin dosing between diagnosis and 7 years. 17 patients had an increase in toxin dosing with a mean dose increase of 70 units.

Conclusion: The vast majority of patients require an increase toxin doses during the course of the disease. Cervical dystonia is a chronic illness, dose increases have major implications- botulinum toxin is a dose limited therapeutic option. Identifying the cause for dose increases and alternative options would be prudent in mitigating risk of toxicity and improving outcomes.

To cite this abstract in AMA style:

S. Rafee, M. Hutchinson. Changes in botulinum toxin dosing in cervical dystonia over 7 years [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/changes-in-botulinum-toxin-dosing-in-cervical-dystonia-over-7-years/. Accessed May 12, 2025.
  • Tweet
  • Email
  • Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/changes-in-botulinum-toxin-dosing-in-cervical-dystonia-over-7-years/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • VIT-D and Tics Movement Disorder
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley